#Virtual Clinical Trials Market Share
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
In February 2021, Tumblr had 518.6 million blog accounts.
Text
Virtual Clinical Trials Market Size, Share & Revenue Projections to 2032
The global Virtual Clinical Trials Market Revenue is poised for significant growth from 2024 to 2032, according to SNS Insider. This surge is driven by increasing adoption of digital healthcare technologies, rising focus on patient-centric approaches, and a growing need to optimize clinical trial operations.
Virtual clinical trials, also known as decentralized clinical trials, leverage telemedicine, digital monitoring tools, and data analytics to streamline the traditional clinical trial process. By removing geographic barriers and reducing patient burden, these trials offer faster recruitment, enhanced data collection, and cost efficiencies. These advantages have led to widespread adoption by pharmaceutical companies, contract research organizations, and regulatory bodies.
Moreover, governments and private stakeholders are increasingly investing in virtual clinical trial platforms to support advancements in personalized medicine and innovative drug development. Key players are focusing on strategic collaborations, technological innovations, and process improvements to cater to evolving industry demands.
Get Free Sample Report @ Click Here
Key Market Drivers and Opportunities
The virtual clinical trials market is underpinned by several transformative trends:
Advancements in Digital Health Tools: Wearable devices, mobile applications, and telehealth platforms are playing a pivotal role in enhancing patient monitoring and engagement.
Patient-Centric Approaches: Virtual trials prioritize patient convenience by enabling remote participation, fostering higher retention and compliance rates.
Regulatory Flexibility: Regulatory authorities worldwide are recognizing the benefits of virtual trials, leading to favorable frameworks and guidelines that encourage adoption.
Challenges and Future Outlook
Despite its potential, the virtual clinical trials market faces challenges such as data security concerns, integration issues, and the digital divide in low-resource settings. However, with ongoing technological advancements and increased emphasis on inclusive trial designs, the industry is set to overcome these barriers.
The report by SNS Insider highlights that stakeholders must prioritize innovation, compliance, and scalability to capitalize on the immense opportunities this market offers in the forecast period.
About Us
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us: Akash Anand – Head of Business Development & Strategy Email: [email protected] Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
#Virtual Clinical Trials Market#Virtual Clinical Trials Market Size#Virtual Clinical Trials Market Share#Virtual Clinical Trials Market Growth#Market Research
0 notes
Text
Pharma Engagement Solutions: Leveraging Technology to Improve HCP Interactions
In the competitive pharmaceutical industry, effective engagement with healthcare professionals (HCPs) is essential for building trust, improving communication, and driving business outcomes. With the rise of digital tools and data-driven strategies, pharma engagement solutions are helping companies transform their approach to HCP interactions. These solutions aim to create meaningful connections through personalized, multichannel outreach, ultimately enhancing the overall healthcare ecosystem.
What Are Pharma Engagement Solutions?
Pharma engagement solutions encompass a range of tools, platforms, and strategies designed to improve interactions between pharmaceutical companies and HCPs. The goal is to provide timely, relevant, and personalized information that supports HCPs in making informed decisions for their patients.
Key components include:
Data-Driven Insights: Leveraging real-time analytics to understand HCP preferences and needs.
Multichannel Outreach: Connecting via email, virtual meetings, webinars, and in-person visits.
Personalized Content: Tailoring information to align with the specific interests of HCPs.
The Importance of Effective Engagement in Pharma
Engagement is more than just communication; it’s about fostering trust and long-term partnerships. Effective engagement:
Enhances Knowledge Sharing: Provides HCPs with valuable insights about new drugs, treatments, and clinical trials.
Builds Strong Relationships: Establishes credibility and positions the pharma company as a trusted partner.
Improves Patient Outcomes: By equipping HCPs with the right information, companies help improve patient care quality.
Technological Innovations Driving Pharma Engagement Solutions
Modern engagement strategies leverage cutting-edge technology to improve efficiency and effectiveness.
a. Customer Relationship Management (CRM) Platforms
CRM tools centralize HCP data, enabling companies to track interactions and preferences. Platforms like these provide actionable insights for more targeted engagement.
b. Artificial Intelligence (AI) and Machine Learning
AI-powered tools analyze data to predict HCP behavior, recommend next-best actions, and optimize communication strategies.
c.Telemedicine Integration
Virtual platforms enable seamless connections with HCPs through video consultations, webinars, and e-detailing. This approach has gained traction post-pandemic as a convenient alternative to in-person meeting.
Personalization: The Core of Pharma Engagement Solutions
A one-size-fits-all approach no longer works in the pharmaceutical industry. Personalization is a cornerstone of modern engagement strategies.
Tailored Messaging: Providing relevant information based on an HCP’s specialty, location, and patient demographics.
Dynamic Content Delivery: Using AI tools to deliver the right message at the right time through the preferred channel.
Feedback Loops: Collecting and acting on HCP feedback to continuously refine engagement strategies.
Challenges in Pharma Engagement
Despite the benefits, implementing pharma engagement solutions comes with challenges:
Data Privacy: Ensuring compliance with regulations like GDPR and HIPAA while managing sensitive HCP data.
Technology Adoption: Encouraging HCPs to embrace new digital tools and platforms.
Regulatory Compliance: Crafting compliant marketing messages that adhere to strict industry guideline.
Benefits of Pharma Engagement Solutions
By addressing these challenges, companies can unlock significant benefits:
Stronger Relationships: Personalized and consistent interactions build trust and loyalty.
Improved ROI: Targeted strategies ensure efficient use of resources, boosting return on investment.
Better Patient Care: Empowering HCPs with the right tools and information enhances their ability to deliver effective treatments.
Emerging Trends in Pharma Engagement Solutions
As technology evolves, pharma engagement solutions are becoming more innovative:
Virtual Reality (VR) and Augmented Reality (AR): These tools offer immersive ways to demonstrate product efficacy or train HCPs.
AI-Driven Chatbots: Automating routine queries to provide 24/7 support for HCPs.
Omnichannel Marketing: Integrating digital and traditional channels for a seamless experience.
Conclusion
Pharma engagement solutions are transforming how pharmaceutical companies interact with HCPs. By leveraging data, personalization, and advanced technology, these solutions help build stronger relationships, foster trust, and enhance patient outcomes. As the industry continues to evolve, staying ahead with innovative engagement strategies is essential for success.
0 notes
Text
Understanding Artificial Intelligence Market: Trends and Growth Drivers
The global artificial intelligence market size is expected to reach USD 1,811.75 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 36.6% from 2024 to 2030. Artificial Intelligence (AI) denotes the concept and development of computing systems capable of performing tasks customarily requiring human assistance, such as decision-making, speech recognition, visual perception, and language translation. AI uses algorithms to understand human speech, visually recognize objects, and process information. These algorithms are used for data processing, calculation, and automated reasoning. Artificial intelligence researchers continuously improve algorithms for various aspects, as conventional algorithms have drawbacks regarding accuracy and efficiency.
These advancements have led manufacturers and technology developers to focus on developing standard algorithms. Recently, several developments have been carried out for enhancing artificial intelligence algorithms. For instance, in May 2020, International Business Machines Corporation announced a wide range of new AI-powered services and capabilities, namely IBM Watson AIOps, for enterprise automation. These services are designed to help automate the IT infrastructures and make them more resilient and cost reduction.
Gather more insights about the market drivers, restrains and growth of the Artificial Intelligence Market
Artificial Intelligence Market Report Highlights
• The advent of big data is expected to be the cause of the growth of the AI market as a large volume of data is needed to be captured, stored, and analyzed.
• The increasing demand for image processing and identification is expected to drive industry growth.
• AI can analyze vast amounts of data to identify patterns and anomalies that might indicate a cyberattack. This allows for faster and more precise threat detection subsequently fostering adoption of AI in cybersecurity applications.
• By using AI for predictive maintenance, process automation, and supply chain optimization, businesses can streamline workflows, reduce costs, and ensure smooth delivery of their offerings.
• North America dominated the market and accounted for a share of over 36.8% of global revenue in 2022.
• One of the significant concerns restraining industry growth is the need for a large amount of data to train AI systems for character and image recognition.
Browse through Grand View Research's Next Generation Technologies Industry Research Reports.
• The global cloud logistics market size was estimated at USD 21.55 billion in 2024 and is projected to grow at a CAGR of 13.9% from 2025 to 2030.
• The global AI in education market size was estimated at USD 5.88 billion in 2024 and is projected to grow at a CAGR of 31.2% from 2025 to 2030.
Artificial Intelligence Market Segmentation
Grand View Research has segmented the global artificial intelligence market based on solution, technology, function, end-use, and region:
Artificial Intelligence Solution Outlook (Revenue, USD Billion, 2017 - 2030)
• Hardware
o Accelerators
o Processors
o Memory
o Network
• Software
• Services
o Professional
o Managed
Artificial Intelligence Technology Outlook (Revenue, USD Billion, 2017 - 2030)
• Deep Learning
• Machine Learning
• Natural Language Processing (NLP)
• Machine Vision
• Generative AI
Artificial Intelligence Function Outlook (Revenue, USD Billion, 2017 - 2030)
• Cybersecurity
• Finance and Accounting
• Human Resource Management
• Legal and Compliance
• Operations
• Sales and Marketing
• Supply Chain Management
Artificial Intelligence End-use Outlook (Revenue, USD Billion, 2017 - 2030)
• Healthcare
o Robot Assisted Surgery
o Virtual Nursing Assistants
o Hospital Workflow Management
o Dosage Error Reduction
o Clinical Trial Participant Identifier
o Preliminary Diagnosis
o Automated Image Diagnosis
• BFSI
o Risk Assessment
o Financial Analysis/Research
o Investment/Portfolio Management
o Others
• Law
• Retail
• Advertising & Media
• Automotive & Transportation
• Agriculture
• Manufacturing
• Others
Artificial Intelligence Regional Outlook (Revenue, USD Billion, 2017 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
• Middle East and Africa (MEA)
o KSA
o UAE
o South Africa
Order a free sample PDF of the Artificial Intelligence Market Intelligence Study, published by Grand View Research.
#Artificial Intelligence Market#Artificial Intelligence Market Analysis#Artificial Intelligence Market Size#Artificial Intelligence Market Share
0 notes
Text
Clinical Trials Market Comprehensive Analysis and Future Estimations by 2030
In 2023, the global clinical trials market was valued at USD 80.7 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. Market growth was notably influenced by the COVID-19 pandemic, which in 2020 led to increased demand for both virtual and traditional clinical trials. Many companies made significant investments in developing new drugs to alleviate the burden of COVID-19 on healthcare systems. For instance, Synairgen plc and Parexel partnered on a Phase III study in 2020 to test the effectiveness of Interferon-beta (IFN-beta) treatment for COVID-19 patients. Additionally, technological advancements, a rising incidence of chronic diseases, the globalization of clinical trials, increased demand for personalized medicine, and a growing reliance on Contract Research Organizations (CROs) for conducting research activities are all expected to contribute to market growth.
The COVID-19 pandemic also brought about changes in how clinical trials were conducted, with regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issuing guidelines to support decentralized and virtual clinical trials during the pandemic. This shift, along with the urgent need for new treatments, led to the adoption of fast-track clinical trials, providing new growth opportunities for the clinical trials market.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Supportive government initiatives are another driver of market growth. For example, the World Health Organization (WHO) launched the Solidarity trial, an international effort to evaluate potential treatments for COVID-19 by comparing four treatments against the standard of care. In May 2020, WHO also announced an international coalition to develop multiple vaccine candidates simultaneously, naming this effort the Solidarity trial for vaccines.
Moreover, the increasing use of CRO services allows manufacturers and sponsors to focus on production capabilities and enhance in-house processes. CROs offer a wide range of services from drug discovery to post-marketing surveillance, which has simplified operations for small and mid-sized pharmaceutical and biotech companies by allowing them to outsource R&D activities, reducing infrastructure costs. For example, in November 2023, Syneos Health entered into an agreement with GoBroad Healthcare Group, expanding its clinical trial capabilities across multiple therapeutic areas in China.
Sponsors Segmentation Insights:
In 2023, pharmaceutical and biopharmaceutical companies accounted for the largest revenue share in the clinical trials market. This dominance is due to the industry’s high level of interest and financial investment in drug research and development. While basic research in academic labs is primarily funded by grants from the National Institutes of Health (NIH), the pharmaceutical industry bears the substantial costs associated with discovering and testing new drugs on animals and humans. Clinical trials represent a major expense, with the cost to bring a new drug to market ranging from USD 266 million to USD 802 million. In the U.S., approximately 75% of clinical trial funding comes from corporate sponsors.
The patient recruitment and retention segment captured a significant market share in 2023. The growing number of clinical studies worldwide has increased the demand for patient recruitment services. Increased funding for clinical research and widespread adoption of digital technologies are further supporting this growth. The market expansion is also driven by large investments in R&D, government support, and the presence of major CROs that provide comprehensive services, including patient recruitment, with active participation from multinational pharmaceutical and biopharmaceutical companies.
The data management segment also held a notable share in 2023 and is expected to maintain this trend over the forecast period. Growth in this segment is driven by the increasing adoption of data management services and a trend toward decentralized trials. The integration of advanced technologies like Artificial Intelligence (AI) and Machine Learning (ML) for data entry, analysis, and quality control is further expected to drive demand in this segment.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
0 notes
Text
Clinical Trials Market Revenue, Share and Growth Rate to 2030
In 2023, the global clinical trials market was valued at USD 80.7 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. Market growth was notably influenced by the COVID-19 pandemic, which in 2020 led to increased demand for both virtual and traditional clinical trials. Many companies made significant investments in developing new drugs to alleviate the burden of COVID-19 on healthcare systems. For instance, Synairgen plc and Parexel partnered on a Phase III study in 2020 to test the effectiveness of Interferon-beta (IFN-beta) treatment for COVID-19 patients. Additionally, technological advancements, a rising incidence of chronic diseases, the globalization of clinical trials, increased demand for personalized medicine, and a growing reliance on Contract Research Organizations (CROs) for conducting research activities are all expected to contribute to market growth.
The COVID-19 pandemic also brought about changes in how clinical trials were conducted, with regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issuing guidelines to support decentralized and virtual clinical trials during the pandemic. This shift, along with the urgent need for new treatments, led to the adoption of fast-track clinical trials, providing new growth opportunities for the clinical trials market.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Supportive government initiatives are another driver of market growth. For example, the World Health Organization (WHO) launched the Solidarity trial, an international effort to evaluate potential treatments for COVID-19 by comparing four treatments against the standard of care. In May 2020, WHO also announced an international coalition to develop multiple vaccine candidates simultaneously, naming this effort the Solidarity trial for vaccines.
Moreover, the increasing use of CRO services allows manufacturers and sponsors to focus on production capabilities and enhance in-house processes. CROs offer a wide range of services from drug discovery to post-marketing surveillance, which has simplified operations for small and mid-sized pharmaceutical and biotech companies by allowing them to outsource R&D activities, reducing infrastructure costs. For example, in November 2023, Syneos Health entered into an agreement with GoBroad Healthcare Group, expanding its clinical trial capabilities across multiple therapeutic areas in China.
Sponsors Segmentation Insights:
In 2023, pharmaceutical and biopharmaceutical companies accounted for the largest revenue share in the clinical trials market. This dominance is due to the industry’s high level of interest and financial investment in drug research and development. While basic research in academic labs is primarily funded by grants from the National Institutes of Health (NIH), the pharmaceutical industry bears the substantial costs associated with discovering and testing new drugs on animals and humans. Clinical trials represent a major expense, with the cost to bring a new drug to market ranging from USD 266 million to USD 802 million. In the U.S., approximately 75% of clinical trial funding comes from corporate sponsors.
The patient recruitment and retention segment captured a significant market share in 2023. The growing number of clinical studies worldwide has increased the demand for patient recruitment services. Increased funding for clinical research and widespread adoption of digital technologies are further supporting this growth. The market expansion is also driven by large investments in R&D, government support, and the presence of major CROs that provide comprehensive services, including patient recruitment, with active participation from multinational pharmaceutical and biopharmaceutical companies.
The data management segment also held a notable share in 2023 and is expected to maintain this trend over the forecast period. Growth in this segment is driven by the increasing adoption of data management services and a trend toward decentralized trials. The integration of advanced technologies like Artificial Intelligence (AI) and Machine Learning (ML) for data entry, analysis, and quality control is further expected to drive demand in this segment.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
0 notes
Text
Pediatric Clinical Trials Market Trends and Opportunities: Global Outlook (2023-2032)
The global demand for pediatric clinical trials was valued at USD 14845.5 Million in 2022 and is expected to reach USD 22783.2 Million in 2030, expanding at a CAGR of 5.5% between 2023 and 2030.
Pediatric clinical trials are essential for understanding how medical treatments, therapies, and vaccines affect children, who often respond differently to medications than adults. These trials are specifically designed to evaluate the safety, dosage, and efficacy of interventions in infants, children, and adolescents, ensuring that treatments are safe and effective for young patients. Given the ethical and regulatory complexities, pediatric trials require careful oversight, with special protocols to protect the young participants' rights, safety, and well-being. Conducting pediatric clinical trials involves challenges like limited patient populations, ethical considerations around informed consent, and the need for age-appropriate formulations and delivery methods. Despite these challenges, pediatric trials are critical to advancing child-specific medical care, helping to fill knowledge gaps and ensuring that children receive therapies that are scientifically validated for their age group. Recent innovations, such as adaptive trial designs and the use of biomarkers, have improved the efficiency and accuracy of pediatric trials, supporting more personalized and effective treatments for children.
The pediatric clinical trials market is influenced by several key trending factors, including:
Rising Prevalence of Pediatric Diseases: Increased rates of chronic conditions in children, such as asthma, diabetes, and neurological disorders, drive demand for pediatric-specific therapies and clinical trials.
Focus on Personalized Medicine: The growing trend towards personalized medicine creates demand for trials that focus on tailoring treatments based on a child's unique genetic and biological profile, improving outcomes and minimizing side effects.
Government and Regulatory Support: Regulatory agencies like the FDA and EMA are incentivizing pediatric trials through initiatives and funding, as well as offering pediatric exclusivity extensions, which encourage pharmaceutical companies to invest in trials for children.
Advances in Genomic and Biomarker Research: Improvements in genomics and biomarker identification are enabling trials to identify specific patient subgroups and track treatment responses more accurately, leading to better-targeted pediatric therapies.
Innovative Trial Designs: Adaptive trial designs, virtual trials, and decentralized models are emerging to address recruitment and retention challenges in pediatric populations, improving accessibility and efficiency.
Increased Awareness and Advocacy: Patient advocacy groups and public awareness campaigns are emphasizing the importance of pediatric research, which boosts trial participation rates and fosters collaboration between research institutions and families.
Expansion of Rare Disease Research: With a growing focus on rare diseases, more pediatric trials are targeting rare genetic and congenital conditions, creating new opportunities for innovation and targeted treatments in the pediatric population.
Ethical Advances and Patient-Centric Approaches: The trend toward patient-centered trials, with age-appropriate consent processes and child-friendly trial environments, is improving recruitment and retention in pediatric studies.
Technological Innovations: The use of mobile devices, wearables, and remote monitoring tools allows researchers to gather real-time health data from children in a less invasive manner, improving trial compliance and data accuracy.
Collaborative Efforts Among Stakeholders: Partnerships between academic institutions, pharmaceutical companies, government agencies, and nonprofit organizations are increasing, fostering resource-sharing and accelerating advancements in pediatric drug development.
Access Complete Report - https://www.credenceresearch.com/report/pediatric-clinical-trials-market
Key Players
Synteract
ICON Plc
Syneos Health
Medpace Inc
PPD Inc
Premier Research
LabCorp Drug Development
QPS Holdings
Pfizer Inc
The Emmes Company LLC
IQVIA Inc
Others
Growth opportunities in the pediatric clinical trials market are being shaped by various factors that address the unique needs of young patients and the evolving landscape of pediatric healthcare. Key opportunities include:
Expansion of Precision Medicine: As precision medicine advances, there is a growing need for pediatric trials that tailor treatments to children’s genetic, biological, and environmental factors, paving the way for more personalized and effective therapies.
Increased Focus on Rare Pediatric Diseases: The prevalence of rare and genetic conditions in children creates a significant demand for specialized clinical trials, as pharmaceutical companies and researchers work to develop targeted therapies for underserved patient populations.
Growth in Pediatric Oncology Trials: Pediatric cancer treatments remain a high-priority area, with opportunities for clinical trials to develop therapies that improve outcomes and reduce side effects specific to childhood cancers.
Development of Age-Appropriate Formulations: There is an opportunity for pharmaceutical companies to innovate in developing child-friendly formulations, such as liquids or chewables, which improve adherence and accessibility for pediatric patients.
Use of Digital Health Technologies: Integrating wearables, mobile apps, and remote monitoring technologies into trials offers opportunities for collecting real-time data, enhancing patient engagement, and allowing participation from home, which is particularly valuable in pediatric studies.
Rise of Decentralized and Hybrid Trial Models: Decentralized trials and hybrid models improve trial access for children and families by minimizing travel requirements, thereby increasing enrollment and diversity while reducing patient burden.
Global Expansion and Emerging Markets: There are untapped markets for pediatric clinical trials in regions with emerging healthcare systems, where unmet medical needs in pediatric care provide opportunities for trials to reach a broader patient base.
Collaboration with Patient Advocacy Groups: Partnering with advocacy organizations focused on children’s health can boost trial awareness, foster recruitment, and facilitate trial design that aligns with the needs and expectations of pediatric patients and their families.
Government Incentives and Regulatory Support: Increasing government incentives and regulatory support for pediatric drug development, such as priority review vouchers and pediatric exclusivity extensions, encourage more pharmaceutical companies to invest in pediatric trials.
Artificial Intelligence and Data Analytics: The use of AI and advanced data analytics in pediatric clinical trials presents an opportunity to streamline patient identification, predict trial outcomes, optimize trial designs, and enhance data interpretation for more accurate results.
Segmentation
By Disease or Condition
Oncology Trials
Pediatric Infectious Disease Trials
Neurological Disorders Trials
Pediatric Respiratory Trials
By Age Groups
Infants (0-2 years)
Children (2-11 years)
Adolescents (12-17 years)
By Therapeutic Approach
Pharmacological Trials
Device Trials
Behavioral Intervention Trials
By Trial Design
Randomized Controlled Trials (RCTs)
Non-Randomized Trials
Adaptive Trials
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Pediatric Hospitals
By Regulatory Considerations
Regulatory Services
Compliance Consulting
By Technology Adoption
Pediatric Biomarker Studies
Pediatric Pharmacogenomics Trials
Browse the full report – https://www.credenceresearch.com/report/pediatric-clinical-trials-market
Contact Us:
Phone: +91 6232 49 3207
Email: [email protected]
Website: https://www.credenceresearch.com
0 notes
Text
Clinical Trials Market Research Report — Global Forecast till 2030
The global clinical trials market reached a valuation of USD 80.7 billion in 2023, with an expected compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. A significant increase in market growth was observed in 2020 due to the COVID-19 pandemic, impacting both virtual and traditional clinical trials. Many pharmaceutical and biotech companies prioritized novel drug development in response to the pandemic, seeking to reduce the impact of COVID-19 on patient health. An example of such efforts was in 2020, when Synairgen plc partnered with Parexel for a Phase III trial evaluating Interferon-beta (IFN-beta) as a treatment for COVID-19. The market's positive growth is also influenced by rapid advancements in technology, the rising prevalence of chronic diseases, globalization in clinical trials, a push for personalized medicine, and increased demand for contract research organizations (CROs) to support research activities.
The pandemic also changed how clinical trials were conducted. Regulatory agencies like the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issued guidelines during COVID-19 to facilitate decentralized and virtual trials. These adaptations helped support remote methods, like telehealth and home-based patient monitoring, to continue trials despite social distancing measures. This evolving approach to research and development, driven by the urgency of finding new treatment options, led to the adoption of fast-track clinical trials. As a result, the clinical trials market is expected to continue expanding as new opportunities emerge for faster, more flexible trial designs.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Government support and initiatives are also playing a crucial role in enhancing market growth potential. For instance, the World Health Organization (WHO) launched the Solidarity trial, a large-scale international clinical trial aiming to identify effective COVID-19 treatments. This trial tested multiple treatments against a standard care approach to evaluate their efficacy in combatting COVID-19. In May 2020, the WHO also initiated an international collaboration for the rapid development of multiple vaccine candidates, known as the Solidarity Vaccine Trials, to accelerate COVID-19 vaccine development.
Phase Segmentation Insights:
The Phase III segment dominated the market, capturing 53.3% of the total revenue share in 2023. Phase III trials are a significant contributor to market growth due to the high volume of participants involved. The median cost for a single Phase III trial exceeds USD 19.0 million. Phase III trials are essential for assessing drug efficacy and safety on a larger scale, requiring a substantial number of participants and often a more extended treatment duration than previous phases. According to a clinical trial logistics survey conducted by Nice Insights, 35% of Phase III trials are outsourced to CROs, a figure expected to grow as more investigational drugs progress to Phase III.
The Phase II segment is also projected to grow considerably throughout the forecast period. Phase II trials are the second most expensive stage after Phase III and typically involve two parts. The first part focuses on exploring a range of doses along with initial efficacy studies, while the second part aims to determine the optimal dose. Phase II trials are critical in oncology research, where effective dosing is paramount. According to FDA estimates, approximately 33% of investigational drugs are in Phase II trials. A significant number of oncology-related therapies and vaccines are currently in Phase II, which is helping drive the growth of this segment. The rising number of both industry-sponsored and independent clinical trials in Phase II, as well as the complex nature of these trials and the international expansion of clinical research, are factors contributing to the growth of the clinical trials market.
Overall, the clinical trials market is experiencing strong momentum driven by increasing demands for innovative medical treatments, regulatory adjustments for flexible trial processes, and significant financial investments. As the need for more efficient and effective clinical research rises, particularly in areas like oncology and infectious diseases, the market is well-positioned to see sustained growth over the coming years.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
#Clinical Trials Market Research#Clinical Trials Market Overview#Clinical Trials Market Size#Clinical Trials Industry
0 notes
Text
Clinical Trials Market Growth Drivers With Outlook And Opportunity Forecast To 2030
The global clinical trials market reached a valuation of USD 80.7 billion in 2023, with an expected compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. A significant increase in market growth was observed in 2020 due to the COVID-19 pandemic, impacting both virtual and traditional clinical trials. Many pharmaceutical and biotech companies prioritized novel drug development in response to the pandemic, seeking to reduce the impact of COVID-19 on patient health. An example of such efforts was in 2020, when Synairgen plc partnered with Parexel for a Phase III trial evaluating Interferon-beta (IFN-beta) as a treatment for COVID-19. The market's positive growth is also influenced by rapid advancements in technology, the rising prevalence of chronic diseases, globalization in clinical trials, a push for personalized medicine, and increased demand for contract research organizations (CROs) to support research activities.
The pandemic also changed how clinical trials were conducted. Regulatory agencies like the U.S. FDA, European Medicines Agency (EMA), National Institutes of Health (NIH), and China’s National Medical Products Administration issued guidelines during COVID-19 to facilitate decentralized and virtual trials. These adaptations helped support remote methods, like telehealth and home-based patient monitoring, to continue trials despite social distancing measures. This evolving approach to research and development, driven by the urgency of finding new treatment options, led to the adoption of fast-track clinical trials. As a result, the clinical trials market is expected to continue expanding as new opportunities emerge for faster, more flexible trial designs.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Government support and initiatives are also playing a crucial role in enhancing market growth potential. For instance, the World Health Organization (WHO) launched the Solidarity trial, a large-scale international clinical trial aiming to identify effective COVID-19 treatments. This trial tested multiple treatments against a standard care approach to evaluate their efficacy in combatting COVID-19. In May 2020, the WHO also initiated an international collaboration for the rapid development of multiple vaccine candidates, known as the Solidarity Vaccine Trials, to accelerate COVID-19 vaccine development.
Phase Segmentation Insights:
The Phase III segment dominated the market, capturing 53.3% of the total revenue share in 2023. Phase III trials are a significant contributor to market growth due to the high volume of participants involved. The median cost for a single Phase III trial exceeds USD 19.0 million. Phase III trials are essential for assessing drug efficacy and safety on a larger scale, requiring a substantial number of participants and often a more extended treatment duration than previous phases. According to a clinical trial logistics survey conducted by Nice Insights, 35% of Phase III trials are outsourced to CROs, a figure expected to grow as more investigational drugs progress to Phase III.
The Phase II segment is also projected to grow considerably throughout the forecast period. Phase II trials are the second most expensive stage after Phase III and typically involve two parts. The first part focuses on exploring a range of doses along with initial efficacy studies, while the second part aims to determine the optimal dose. Phase II trials are critical in oncology research, where effective dosing is paramount. According to FDA estimates, approximately 33% of investigational drugs are in Phase II trials. A significant number of oncology-related therapies and vaccines are currently in Phase II, which is helping drive the growth of this segment. The rising number of both industry-sponsored and independent clinical trials in Phase II, as well as the complex nature of these trials and the international expansion of clinical research, are factors contributing to the growth of the clinical trials market.
Overall, the clinical trials market is experiencing strong momentum driven by increasing demands for innovative medical treatments, regulatory adjustments for flexible trial processes, and significant financial investments. As the need for more efficient and effective clinical research rises, particularly in areas like oncology and infectious diseases, the market is well-positioned to see sustained growth over the coming years.
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
#Clinical Trials Market Research#Clinical Trials Market Overview#Clinical Trials Market Size#Clinical Trials Industry
0 notes
Text
Expanding Access, The Growth of Virtual Clinical Trials Worldwide
0 notes
Text
Virtual Clinical Trials Market Future: Trends, Challenges, and Opportunities
Virtual Clinical Trials Market Outlook, Scope & Overview:
Industry reports indicate that the global virtual clinical trials market was valued at USD 8.39 billion in 2023 and is projected to reach USD 13.17 billion by 2031, growing at a CAGR of 5.8% over the forecast period 2024-2031.
Technological Advancements to Drive Growth of Global Virtual Clinical Trials Market
The adoption of virtual clinical trial solutions will continue to influence global market revenues. The shift towards virtual and decentralized clinical trials is driven by the need for more flexible, efficient, and patient-centric trial designs that can enhance data collection and reduce operational costs.
As a product segment, remote patient monitoring and digital data collection solutions currently hold a significant share of the global virtual clinical trials market. This segment is anticipated to grow at a year-over-year rate of 5.8% in 2024 over 2023 and reach USD 13.17 billion in revenues by 2031. The increasing demand for real-time data access and the need to overcome geographical and logistical challenges in clinical trials are expected to drive market growth.
Virtual Clinical Trials Solutions – Market Dynamics
Drivers:
Virtual clinical trials are witnessing significant growth due to their ability to provide greater flexibility, enhance patient engagement, and improve the efficiency of trial processes. The advancements in digital health technologies, such as remote monitoring devices, telemedicine platforms, and electronic data capture systems, are key factors driving the adoption of virtual clinical trials. Additionally, the need for faster trial recruitment and the growing focus on patient-centric approaches are further propelling market growth.
Restraints:
Despite the growth potential, challenges such as data privacy concerns, regulatory hurdles, and the complexity of integrating virtual trial technologies with existing systems are hindering the widespread adoption of virtual clinical trials. Moreover, issues related to technology accessibility, patient engagement, and the need for robust cybersecurity measures pose additional challenges to market expansion.
Virtual Clinical Trials Solutions – Market Outlook
The proven benefits of virtual clinical trials in enhancing trial efficiency, improving patient participation, and reducing operational costs have contributed to the market's growth. Virtual clinical trials are expected to witness increased adoption across major markets, including North America, Europe, and Asia Pacific, driven by advancements in digital health technologies and the growing emphasis on decentralized trial models.
Global Virtual Clinical Trials Market
The rise in demand for virtual clinical trials in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global virtual clinical trials market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of virtual trial solutions, supported by favorable regulatory frameworks and increasing investments in digital healthcare infrastructure.
Key Players in the Virtual Clinical Trials Solutions Market
Leading companies in the virtual clinical trials solutions market include Medidata Solutions, Parexel International, Veeva Systems, and Oracle Corporation. These companies are at the forefront of developing and commercializing advanced virtual trial platforms and technologies for various clinical research applications, including remote monitoring, data management, and patient engagement.
In conclusion, the global virtual clinical trials market is poised for substantial growth over the forecast period, driven by technological advancements, increasing demand for decentralized trial models, and the expanding adoption of digital health solutions across diverse clinical research settings.
Other Trending Reports
Artificial Intelligence in Ultrasound Imaging Industry Growth
Growth Hormone Deficiency Industry Growth
Patient Registry Software Industry Growth
Contrast Media/Contrast Agent Industry Growth
#Virtual Clinical Trials Market#Virtual Clinical Trials Market Size#Virtual Clinical Trials Market Share#Virtual Clinical Trials Market Trends#Virtual Clinical Trials Market Growth#Virtual Clinical Trials Market Analysis#Virtual Clinical Trials Market Outlook
0 notes
Text
The Clinical Trial Management System Market is projected to grow from USD 2075 million in 2024 to an estimated USD 5981.71 million by 2032, with a compound annual growth rate (CAGR) of 14.15% from 2024 to 2032.The Clinical Trial Management System (CTMS) market has witnessed remarkable growth in recent years, driven by advancements in healthcare technology and the increasing complexity of clinical trials. CTMS is a software solution that supports the planning, tracking, and management of clinical trials, enabling pharmaceutical companies, Contract Research Organizations (CROs), and academic research institutions to streamline their processes. As the demand for more efficient drug development and research intensifies, CTMS has become an essential tool for optimizing clinical trial operations.
Browse the full report at https://www.credenceresearch.com/report/clinical-trial-management-systems-market
Market Overview
The CTMS market is projected to experience substantial growth, driven by an increasing number of clinical trials and the expanding pharmaceutical and biotechnology industries. According to recent industry reports, the market is expected to grow at a compound annual growth rate (CAGR) of around 13-14% from 2023 to 2030. This rapid expansion is attributed to the growing adoption of CTMS solutions, technological advancements, and the rising need to manage large volumes of clinical data effectively.
Key Drivers of Market Growth
1. Increase in Clinical Trials The rise in the number of clinical trials, especially in emerging markets, is a significant driver for the CTMS market. As more pharmaceutical and biotechnology companies aim to bring new drugs to market, they require systems that can manage complex trial data, regulatory requirements, and patient recruitment. CTMS platforms offer robust solutions to these challenges by ensuring compliance and data integrity while minimizing operational inefficiencies.
2. Technological Advancements With advancements in artificial intelligence (AI), machine learning (ML), and cloud-based solutions, CTMS systems have become more sophisticated, providing better integration, real-time data tracking, and predictive analytics. These innovations allow sponsors and researchers to make informed decisions more quickly and efficiently, reducing trial costs and timelines.
3. Regulatory Compliance The increasing stringency of regulatory guidelines globally has made compliance management crucial for clinical trials. CTMS platforms are equipped with features that ensure adherence to regulatory standards such as Good Clinical Practice (GCP), the International Council for Harmonisation (ICH) guidelines, and the Food and Drug Administration (FDA) regulations. Automated monitoring and audit trail capabilities offered by these systems help sponsors and CROs maintain regulatory compliance seamlessly.
4. Rising Adoption of Decentralized Trials The COVID-19 pandemic accelerated the trend toward decentralized clinical trials, where patient data is collected remotely. CTMS platforms are playing a key role in supporting decentralized trials by enabling remote monitoring, patient data capture, and virtual collaboration between stakeholders. This shift has not only enhanced the reach of clinical trials but has also improved patient retention and engagement.
### **Regional Insights**
The CTMS market is globally segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest market share due to the presence of a robust pharmaceutical and biotechnology industry, as well as supportive regulatory frameworks. However, the Asia Pacific region is anticipated to witness the fastest growth due to increasing R&D activities, growing healthcare infrastructure, and government initiatives to boost clinical trials.
Challenges Facing the CTMS Market
Despite the strong growth trajectory, the CTMS market faces several challenges:
1. High Implementation Costs The initial cost of setting up and implementing a CTMS can be substantial, especially for small- and medium-sized enterprises (SMEs). This can hinder widespread adoption, particularly in developing regions where cost sensitivity is high.
2. Data Integration Issues Clinical trials generate large amounts of data from various sources, including electronic health records (EHRs), wearable devices, and laboratory information management systems (LIMS). Integrating these data streams into a single CTMS platform can be challenging, leading to data silos and inefficiencies.
3. Data Security and Privacy Concerns The growing reliance on cloud-based solutions has raised concerns about data security and privacy. As clinical trial data often includes sensitive patient information, ensuring the security of this data is a significant challenge for CTMS vendors and users alike.
Future Outlook
The future of the CTMS market looks promising, with increasing investments in research and development, advancements in AI and machine learning, and the growing adoption of decentralized trial models. As the demand for more efficient clinical trial management continues to rise, CTMS platforms are poised to play a critical role in optimizing trial operations, improving patient outcomes, and accelerating the drug development process.
Key Player Analysis:
Calyx (formerly Parexel Informatics)
Clario
DATATRAK International, Inc.
IQVIA, Inc.
Laboratory Corporation of America Holdings
Medidata (Dassault Systèmes)
Oracle
PHARMASEAL International Ltd.
RealTime Software Solutions, LLC
SimpleTrials
Veeva Systems
Wipro Limited
Segmentation:
By Type
Enterprise
Site
By Component
Software
Services
By Delivery Mode
Web & Cloud Based
On Premise
By End-user
Pharmaceutical and Biotechnology Firms
Medical Device Firms
CROs & Others
By Region
North America
The U.S
Canada
Mexico
Europe
Germany
France
The U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/clinical-trial-management-systems-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
Clinical Trials Market Size, Share, Growth and Industry Trends 2024 - 2030
The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030.
The market growth spiked in 2020 owing to the COVID-19 pandemic. This growth pattern was witnessed by both virtual clinical trials and traditional ones. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. One such example being, in 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Furthermore, rapid technological evolution, rising prevalence of chronic diseases, globalization of clinical trials, penetration of personalized medicine and a rise in demand for CROs for conducting research activities is expected to positively impact the market growth.
In addition, the COVID-19 pandemic led to changing the ways of conducting upcoming or ongoing clinical trials. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration among several others issued various guidelines for conducting trials during the pandemic to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to offer new avenues to the clinical trials market growth.
Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market
Clinical Trials Market Report Highlights
• The phase III clinical trials segment dominated the market with a 53.3% share in 2023. This can be attributed to the complexity of this phase
• The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers
• North America held 50.3% of the market share in 2023. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth
• Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing patient pool and cost-efficient services.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
• The global healthcare predictive analytics market size was estimated at USD 14.58 billion in 2023 and is projected to grow at a CAGR of 24.0% from 2024 to 2030.
• The global medical animation market size was valued at USD 396.2 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 20.1% from 2024 to 2030.
Clinical Trials Market Segmentation
Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:
Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)
• Phase I
• Phase II
• Phase III
• Phase IV
Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
• Interventional
• Observational
• Expanded Access
Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)
• Autoimmune/Inflammation
o Rheumatoid Arthritis
o Multiple Sclerosis
o Osteoarthritis
o Irritable Bowel Syndrome (IBS)
o Others
• Pain Management
o Chronic Pain
o Acute Pain
• Oncology
o Blood Cancer
o Solid Tumors
o Other
• CNS Condition
o Epilepsy
o Parkinson's Disease (PD)
o Huntington's Disease
o Stroke
o Traumatic Brain Injury (TBI)
o Amyotrophic Lateral Sclerosis (ALS)
o Muscle Regeneration
o Others
• Diabetes
• Obesity
• Cardiovascular
• Others
Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)
• Autoimmune/Inflammation
o Interventional
o Observational
o Expanded Access
• Pain Management
o Interventional
o Observational
o Expanded Access
• Oncology
o Interventional
o Observational
o Expanded Access
• CNS Condition
o Interventional
o Observational
o Expanded Access
• Diabetes
o Interventional
o Observational
o Expanded Access
• Obesity
o Interventional
o Observational
o Expanded Access
• Cardiovascular
o Interventional
o Observational
o Expanded Access
• Others
o Interventional
o Observational
o Expanded Access
Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Others
Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Spain
o Italy
• Asia Pacific
o India
o Japan
o China
o Australia
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
o Colombia
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.
#Clinical Trials Market#Clinical Trials Market size#Clinical Trials Market share#Clinical Trials Market analysis#Clinical Trials Industry
0 notes
Text
Clinical Trial Imaging 2023 Industry Report Potential Growth, Share, Demand And Forecast to 2030
Clinical Trial Imaging Industry Overview
The global clinical trial imaging market size was estimated at USD 1.14 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.60% from 2024 to 2030. The market growth is anticipated to be fueled by the growing biotechnology and pharmaceutical sectors, coupled with rising investments in research and development for the creation of new drugs aimed at treating various diseases. Medical imaging plays a pivotal role in advancing the development of innovative life science products.
Gather more insights about the market drivers, restrains and growth of the Clinical Trial Imaging Market
Despite the ever-changing nature of the medical imaging industry, the biotechnology and pharmaceutical industries are showing sustained growth. This is primarily due to the increased investment in medical imaging companies, as well as the occurrence of mergers and acquisitions that involve the incorporation of cutting-edge imaging technologies to facilitate clinical trials for medical devices.
Advancements in technology are bringing substantial improvements to the collection, evaluation, and submission of clinical trial imaging data. Technology-enabled imaging, especially image analysis software, provides various benefits to clinical studies, such as consistency, data accuracy, adaptability, and compliance. For instance, image analysis software is used to direct and manage a reader by analyzing imaging time points. In addition, the increased use of imaging technology, along with the enhanced power of computing, is expected to drive the usage of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) protocol has come up with standardized methods and imaging procedures with uniform procedures to be implemented for attaining statistical and precise endpoints in clinical trials.
The Covid-19 pandemic has adversely impacted the healthcare system in most countries, leading to a disruption in medical studies, and research activities, and reduced sponsorship for research involving clinical trials. The pandemic hampered the clinical trial timeline as numerous ongoing studies were delayed and planned studies were cancelled. Unfavorable changes in regulations and guidelines, supply chain disruption, recruitment challenges for clinical trials, fear of viral spread, and shutting down of most manufacturers during lockdown have adversely impacted the market. However, introducing virtual imaging trials during the COVID-19 pandemic is expected to open new avenues for adopting these devices. The development of advanced computational models helps better assess CT and radiography images, which are expected to help in the early diagnosis of COVID-19 patients. The market has witnessed a bounce back by 2022 Q2 due to increased R&D activities and improvement in supply and distribution channels.
Many patents have been filed in the realm of enhancing image evaluation and capturing. In addition, imaging core lab provider’s offer patented technologies that are anticipated to assist pharmaceutical companies in reducing their development timelines. As an example, IXICO provides a diagnostic tool called Assessa, which enhances decision-making in clinical trials for conditions related to memory, including schizophrenia, Parkinson's, and Alzheimer's disease, as well as neurological disorders such as dementia and cognitive impairment. However, the high cost of machinery and their installation, and the enormous cost of clinical trials may limit the market growth during the forecast periods. Advancements in technology are bringing substantial improvements to the collection, evaluation, and submit clinical trial imaging data. Technology-enabled imaging especially image analysis software provides various benefits to clinical studies such as consistency, data accuracy, adaptability as well as compliance. For instance, image analysis software is used to direct and manage a reader via analysis of imaging time points.
Browse through Grand View Research's Medical Devices Industry Research Reports.
• The global mobile stroke unit market size was valued at USD 35.80 million in 2023 and is projected to grow at a CAGR of 5.2% from 2024 to 2030. Rising incidence of strokes increased focus on early treatment of stroke patients are driving the demand for efficient and timely stroke care services.
• The global brain tumor diagnosis and therapeutics market size was valued at USD 3.11 billion in 2023 and is projected to grow at a CAGR of 7.1% from 2024 to 2030. The growing launches of brain tumor therapeutics products and the rise in cancer awareness for brain tumor medications drive the market over the forecast period.
Clinical Trial Imaging Market Segmentation
Grand View Research has segmented the clinical trial imaging market on the basis of on service, modality, application, end-use and region:
Clinical Trial Imaging Service Outlook (Revenue, USD Million, 2018 - 2030) • Clinical Trial Design and Consultation Services • Reading and Analytical Services • Operational Imaging Services • System and Technology Support Services • Project and Data Management
Clinical Trial Imaging Modality Outlook (Revenue, USD Million, 2018 - 2030) • Computed Tomography • Magnetic Resonance Imaging • X-Ray • Ultrasound • Optical Coherence Tomography (OCT) • Others
Clinical Trial Imaging Application Outlook (Revenue, USD Million, 2018 - 2030) • NASH • CKD • Diabetes • Cardiovascular Diseases • Ophthalmology • Musculoskeletal • Oncology • Gastroenterology • Pediatrics • Others
Clinical Trial Imaging End-use Outlook (Revenue, USD Million, 2018 - 2030) • Biotechnology and Pharmaceutical companies • Medical Devices Manufacturers • Academic and Government Research Institutes • Contract Research Organizations (CROs) • Others
Clinical Trial Imaging Regional Outlook (Revenue, USD Million, 2018 - 2030) • North America o U.S. o Canada • Europe o UK o Germany o France o Italy o Spain o Denmark o Sweden o Norway • Asia Pacific o India o China o Japan o Australia o Thailand o South Korea • Latin America o Brazil o Mexico o Argentina • Middle East & Africa o South Africa o Saudi Arabia o UAE o Kuwait
Order a free sample PDF of the Clinical Trial Imaging Market Intelligence Study, published by Grand View Research.
Key Companies profiled: • IXICO plc • Navitas Life Sciences • Resonance Health • ProScan Imaging • Radiant Sage LLC • Medpace • Biomedical Systems Corp • Cardiovascular Imaging Technologies • Intrinsic Imaging • BioTelemetry
Recent Developments
• In March 2023, Clario launched a cloud-based image viewer specifically for clinical trials. This innovation aims to streamline medical image analysis and improve its accessibility within the clinical research context
• In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized solutions for cardiac health, which involve analyzing and devising treatment strategies for cardiovascular issues. The partnership is expected to leverage Cleerly's AI-powered platform to examine coronary CT angiography (CCTA) images
0 notes
Text
Inc & Co- Importance of AI in Health Sector
Artificial Intelligence (AI) is revolutionizing the healthcare sector by enhancing efficiency, accuracy, and accessibility. Here are some key areas shared by team Inc & Co where AI is making a significant impact:
1. Diagnosis and Treatment
Enhanced Diagnostics: AI algorithms can analyze medical images, such as X-rays, MRIs, and CT scans, with remarkable accuracy, often surpassing human radiologists. This leads to faster and more precise diagnoses, enabling timely treatment.
Personalized Medicine: AI helps in analyzing patient data to identify patterns and predict how individuals will respond to specific treatments, allowing for more personalized and effective care.
2. Drug Discovery and Development
Accelerated Drug Discovery: AI models can predict how different compounds interact with biological systems, significantly speeding up the process of drug discovery and reducing the costs associated with bringing new drugs to market.
Clinical Trials Optimization: AI helps in identifying suitable candidates for clinical trials and predicting outcomes, making trials more efficient and reducing the time needed to bring new therapies to patients.
3. Healthcare Operations
Efficient Resource Management: AI can optimize the allocation of resources such as hospital beds, staff, and medical equipment, improving the overall efficiency of healthcare facilities.
Predictive Analytics: AI-driven predictive models help in anticipating patient admissions, managing workloads, and planning for potential outbreaks or emergencies.
4. Telemedicine and Remote Care
Virtual Health Assistants: AI-powered chatbots and virtual assistants can provide patients with instant medical advice, answer queries, and schedule appointments, enhancing access to healthcare, especially in remote areas.
Remote Monitoring: AI is integral to remote patient monitoring systems, where wearable devices track vital signs and alert healthcare providers to any anomalies, allowing for early intervention.
5. Patient Care and Experience
Improved Patient Experience: AI-driven tools can streamline administrative tasks such as appointment scheduling, billing, and medical record management, reducing the burden on patients and healthcare providers alike.
Mental Health Support: AI applications are being used to monitor mental health through natural language processing and behavioral analysis, providing support and intervention when necessary.
6. Public Health and Disease Management
Epidemiology and Outbreak Prediction: AI can analyze vast amounts of data from various sources to predict and track the spread of infectious diseases, enabling quicker and more effective public health responses.
Chronic Disease Management: AI systems can assist in managing chronic diseases by continuously monitoring patients and providing personalized recommendations for lifestyle and treatment adjustments.
Conclusion
AI is becoming indispensable in the healthcare sector, transforming how we diagnose, treat, and manage diseases. By improving accuracy, efficiency, and personalization, AI is not only enhancing the quality of care but also making it more accessible to people around the world. As AI technology continues to evolve, its role in healthcare will only become more integral, paving the way for a future where healthcare is more predictive, preventive, and personalized.
Follow team Inc & Co for more such posts!
0 notes
Text
Aramid Fiber Market – Latest Scenario Report And Forecast 2024-2033 | Global Insight Services
Global Insight Services has recently updated its global market reports, now including the latest data for 2024 and projections through 2033.
The global Aramid Fiber market was valued at USD 2.8 Billion in 2022 and it is anticipated to grow up to USD 8.4 Billion by 2032, at a CAGR of 11.6% during the forecast period.
Aramid fiber is a type of synthetic fiber that is heat resistant and strong. It is used in a variety of applications, including bulletproof vests and tires. Aramid fiber is made from a class of polymers called aromatic polyamides. The most common type of aramid fiber is Kevlar.
To Know More@ https://www.globalinsightservices.com/reports/aramid-fiber-market/?utm_id=Pranalip
Market Trends and Drivers
Increasing demand for security & protective measures in various end-use industries such as military and construction is anticipated to boost the demand for aramid fibers over the forecast period. Aramid fiber is widely utilized in the making of protective clothing, equipment, and accessories owing to its excellent fiber, chemical, mechanical, and thermal properties. Protective clothing is specifically designed, treated, and fabricated to protect personnel from hazards that are caused by dangerous work environments and extreme environmental conditions. Some of the protective clothing is designed to protect workers from pollution or infection. Protective clothing is widely utilized in various end-use industries such as healthcare/medical, mining, oil & gas, manufacturing, building & construction, military, and others.
Request Sample@ https://www.globalinsightservices.com/request-sample/GIS20293/?utm_id=Pranalip
Research Objectives
Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region
Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
Identify factors influencing market growth and challenges, opportunities, drivers and restraints
Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.
Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives
Request Customization@ https://www.globalinsightservices.com/request-customization/GIS20293/?utm_id=Pranalip
Global Aramid Fiber Market Segmentation
By Type
Para-aramid Fiber
Meta-aramid Fiber
By Application
Robot-Assisted Surgery
Clinical Trials
Hospital Workflow
Therapy Planning
Wearables
Virtual Assistants
Medical Imaging & Diagnosis
Others
Major Players in the Global Aramid Fiber Market
The overall competitive rivalry remains moderately high in the market studied. The growing presence of big players in the industry is expected to intensify competitive rivalry during the forecast period. The global Bioactive Ingredients Market report includes players such as Rohtex GmbH (Germany), DuPont De Numerous, Inc. (US), Huvis Corporation (South Korea), Hyosung Corp. (South Korea), Kermel (France), Kolon Industries Inc. (South Korea), SRO Aramid (Jiangsu) Co. Ltd. (China), Teijin Ltd. (Japan), Toray Industries, Inc. (Japan), and Yantai Tayho Advanced Materials Co., Ltd. (China) among others.
Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS20293/?utm_id=Pranalip
Research Scope
Scope – Highlights, Trends, Insights. Attractiveness, Forecast
Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Infographic excel data pack, easy to analyze big data
Robust and transparent research methodology
Unmatched data quality and after sales service
Contact Us:
Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: [email protected] Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/
About Global Insight Services:
lobal Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
0 notes
Text
Hot Flashes Market expected to rise | Companies- Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, expected to drive market
The Hot Flashes market growth is driven by factors like increase in the prevalence of Hot Flashes, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Hot Flashes market report also offers comprehensive insights into the Hot Flashes market size, share, Hot Flashes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hot Flashes market size growth forward.
Some of the key highlights from the Hot Flashes Market Insights Report:
Several key pharmaceutical companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others, are developing novel products to improve the Hot Flashes treatment outlook.
The total Hot Flashes market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Hot Flashes market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Hot Flashes Market Landscape
Hot Flashes Overview
Hot flashes (HFs) are a rapid and exaggerated heat dissipation response, consisting of profuse sweating, peripheral vasodilation, and feelings of intense, internal heat. They are triggered by small elevations in core body temperature (Tc) acting within a greatly reduced thermoneutral zone, i.e., the Tc region between the upper (sweating) and lower (shivering) thresholds.
Hot flashes (HFs) are the most common symptom of the climacteric and are reported as feelings of intense warmth along with sweating, flushing, and chills. More than 80% of women experience hot flashes (HFs) during menopause. Defined by transient sensations of heat, sweating, flushing, anxiety, and chills lasting for 1–5 min, HFs can cause considerable distress especially when severe and frequent.
Among various factors reported to be associated with increase in incidence of HFs, a consistent association has been found only with obesity, African descent, lower socioeconomic status, presence of premenstrual syndrome, sedentary lifestyle, and smoking. HFs are characterized by excessive vasodilation of peripheral vasculature to lose heat in the setting of abnormal hypothalamic thermoneutral zone. While normal women initiate mechanisms of heat loss, once core body temperature increases by 0.4°C, women with HFs initiate vasodilatory response with a much smaller increase in core body temperature. It is peripheral vasodilatory response that results in profuse sweating and sensation of intense heat.
Do you know the treatment paradigms for different countries? Download our Hot Flashes Market Sample Report
Recent Highlights from the Hot Flashes Market Report:
In April, Fervent Pharmaceuticals has initiated a virtual at home Phase II clinical trial of its new product to treat the symptoms of moderate to severe hot flashes, night sweats and night-time awakenings due to hot flashes in women. Named M2S Hot Flash Study, the trial will analyse the peri- and post-menopausal therapy to treat hot flashes and night sweats.
In January 2020, Veru Inc, developing novel medicines for the management of prostate cancer, today announced positive top line data interim results from its Phase 2 clinical study of Zuclomiphene citrate, a nonsteroidal oral estrogen receptor agonist, for the treatment of androgen deprivation hormone therapy (ADT) induced hot flashes, also known as vasomotor symptoms, in men who have advanced prostate cancer. Zuclomiphene appears to be well tolerated as there have been no reports of drug related serious adverse events nor drug related severe adverse events and no observations of adverse events of special interest, such as breast enlargement or pain, or venothromboembolic events (blood clots in legs or lungs, or stroke) in the safety database for the Phase 2 clinical study.
Hot Flashes Epidemiology Segmentation
DelveInsight’s Hot Flashes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hot Flashes historical patient pools and forecasted Hot Flashes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hot Flashes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Hot Flashes Prevalence
Age-Specific Hot Flashes Prevalence
Gender-Specific Hot Flashes Prevalence
Diagnosed and Treatable Cases of Hot Flashes
Visit for more @ Hot Flashes Epidemiological Insights
Hot Flashes Treatment Market
The Hot Flashes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hot Flashes market trends by analyzing the impact of current Hot Flashes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Hot Flashes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hot Flashes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hot Flashes market in 7MM is expected to witness a major change in the study period 2019-2032.
Hot Flashes Emerging Drugs
Fezolinetant: Astellas Pharma
Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.
Elinzanetant: Bayer
Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes.
Fezolinetant: Ogeda
Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women’s health disorders. Fezolinetant’s mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women. In addition, fezolinetant addresses the cause of PCOS by selectively lowering luteinizing hormone (LH) without affecting follicle-stimulating hormone (FSH) in order to restore the correct LH-to-FSH ratio and permit the restoration of menstrual cycle regularity and fertility. Fezolinetant is also superior to the existing, marketed gonadotropin-releasing hormone (GnRH) ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis.
Zuclomiphene citrate: Veru Inc
Zuclomiphene citrate is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist. Today the Company announced that a Phase 2 clinical trial of Zuclomiphene citrate demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes in men with advanced prostate cancer on ADT therapy.
Hot Flashes Key Companies
Veru Healthcare
Fervent Pharmaceuticals
Ogeda
Bayer
Lundbeck A/S
TherapeuticsMD
MenoGeniX
Mitsubishi Tanabe Pharma
QUE Oncology
Pherin Pharmaceuticals
For more information, visit Hot Flashes Market Analysis, Patient Pool, and Emerging Therapies
Trending Reports by DelveInsight:
C-met Non-small Cell Lung Cancer Market | Car T Cell Therapy for (NHL) Market | Esophageal Squamous Carcinoma Market | Failed Back Surgery Syndrome Market | Gingivitis Market | Neovascular Age-related Macular Degeneration Market | Nephrosclerosis Market |Netherton Syndrome Market | Noonan Syndrome Market | Pulmonary Sarcoidosis Market | Syncope Market | CAR T Cell Therapy for Multiple Myeloma Market | Chronic Spontaneous Urticaria Market | Malignant Pleural Mesothelioma Market | Candidemia Market | Chronic Thromboembolic Pulmonary Hypertension Cteph Market | Down Syndrome Market | Gene and Cell Therapies Targeting CNS Disorders Market | Interstitial Lung Disease Market | Sarcoidosis Market
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Connect with DelveInsight:
LinkedIn | Facebook | Twitter
Contact Us:
Kritika RehaniTeam Lead, Marketing
+91-9650213330
www.delveinsight.com
0 notes